Blair William & Co. IL Grows Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Blair William & Co. IL increased its stake in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 14.1% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,101,325 shares of the company’s stock after purchasing an additional 136,273 shares during the period. Blair William & Co. IL owned approximately 1.14% of Poseida Therapeutics worth $3,216,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after buying an additional 473,746 shares during the period. Renaissance Technologies LLC grew its position in Poseida Therapeutics by 53.4% in the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after acquiring an additional 297,500 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in Poseida Therapeutics by 89.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock valued at $2,648,000 after acquiring an additional 391,801 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Poseida Therapeutics by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock worth $1,749,000 after purchasing an additional 9,672 shares during the period. Finally, Acadian Asset Management LLC lifted its position in shares of Poseida Therapeutics by 9.4% during the second quarter. Acadian Asset Management LLC now owns 399,839 shares of the company’s stock worth $1,165,000 after purchasing an additional 34,321 shares in the last quarter. Institutional investors and hedge funds own 46.87% of the company’s stock.

Poseida Therapeutics Price Performance

PSTX stock opened at $3.37 on Monday. The business’s 50-day moving average is $3.11 and its two-hundred day moving average is $2.95. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.48 and a quick ratio of 2.48. The firm has a market capitalization of $327.33 million, a P/E ratio of -2.83 and a beta of 0.51. Poseida Therapeutics, Inc. has a 1 year low of $1.83 and a 1 year high of $4.27.

Poseida Therapeutics (NASDAQ:PSTX) last issued its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. The firm had revenue of $25.97 million for the quarter, compared to analysts’ expectations of $13.75 million. Analysts anticipate that Poseida Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Poseida Therapeutics in a research note on Tuesday, August 6th.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.